We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) updated its pharmaceutical marketing practice code, creating tougher restrictions on the gifts healthcare professionals can receive, the organization announced.
PhRMA is tentatively supporting the Centers for Medicare & Medicaid Services' (CMS) proposal to collect and share prescription drug plan data, but is concerned that the agency may overreach by using the information to compare different products.
Information on GSCM Ventures' website, including the name of a product it sells, wrongly promotes it as a treatment for obesity, an FDA warning letter said.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has published a consultation paper seeking comment on a proposed hike in industry fees for medical device regulatory activities.
A new congressional report has concluded that the drug industry's increasing investment in R&D is not resulting in sufficient increases in the new drug pipeline and structural changes are necessary to fix a "stagnant" system.
Eli Lilly is denying assertions in two articles in The New York Times that claim the company's own internal documents show that it sought to promote off-label use of the drug among elderly patients with mild dementia.
A bipartisan group of lawmakers is using a recent government report to pressure the Bush administration to increase funding for FDA oversight of direct-to-consumer (DTC) drug advertising and to institute a moratorium on ads for newly approved products.
OTC drugs in very small "convenience-size" packages could qualify for "optional alternative labeling" under a proposed amendment to the FDA's 1999 final rule on standardized format and content requirements for OTC drug labeling in general.